ALAMEDA, Calif., Aug. 15 /PRNewswire-FirstCall/ -- Xenogen Corporation
(Nasdaq: XGEN) announced today that it has completed a private equity
placement, consisting of common stock and warrants, resulting in gross
proceeds of $15 million. Thomas Weisel Partners LLC served as the sole
placement agent for the transaction.
Under the financing, Xenogen sold 5,154,640 shares of its common stock at
$2.91 per share and issued warrants to purchase 1,546,392 shares of common
stock at an exercise price of $3.29 per share. Dallas based Greenway Capital
served as lead investor and the transaction included participation from
existing venture investors, including Abingworth Management Ltd.
The securities sold and issued in connection with the private placement
have not been registered under the Securities Act of 1933, as amended, or any
state securities laws and may not be offered or sold in the United States
absent registration with the Securities and Exchange Commission or an
applicable exemption from the registration requirements. Xenogen has agreed to
file a registration statement covering the resale of the shares of common
stock and the shares of common stock issuable upon exercise of the warrants
acquired in the private placement.
About Xenogen Corporation
Xenogen combines systems biology and low-light optical imaging to create
powerful new biophotonic imaging technology that advances the ability of
scientists to explore genes, proteins, pathogens and tumor cells in living
animals in real time, providing predictive data that is designed to
substantially improve the success rate in drug development. Xenogen
incorporates into living animals the bioluminescent gene that makes a firefly
glow and captures the resulting light using an ultra-sensitive camera and
sophisticated software. This biophotonic imaging technology creates images and
analyzes the data generated on cellular activity, gene expression, spread of
disease or the effect of a new drug candidate. Xenogen's biophotonic imaging
technology is used by leading academics and pharmaceutical and biotechnology
companies to provide more accurate and previously unavailable data intended to
result in the ability to make more timely and cost-effective decisions at
every step in the drug development process.
Xenogen Biosciences, a wholly owned subsidiary of Xenogen, offers more
than 14 years of experience in the transgenic field, providing reliable,
genetically modified custom mouse models in short timelines. The company has
completed more than 2,000 transgenic and 600 gene targeting experiments, with
a greater than 95 percent success rate in delivering transgenic founder or
gene knockout lines to customers.
More information about Xenogen is available on the company's Web site at
http://www.xenogen.com. Xenogen(R), Living Image(R), IVIS(R) and DLIT(TM) are
registered trademarks or trademarks of Xenogen Corporation. http://www.xenogen.com
SOURCE Xenogen Corporation
 back to top
Related links:
http://www.xenogen.com
CONTACT:
William A. Albright, Chief Financial Officer
of Xenogen Corporation, +1-510-291-6100
|
